BRCA1 deficiency sensitizes breast cancer cells to bromodomain and extra-terminal domain (BET) inhibition

[1]  G. Mills,et al.  BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. , 2018, Cancer cell.

[2]  Andrew J. Wilson,et al.  BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer. , 2017, Cell reports.

[3]  Lin Zhang,et al.  Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition , 2017, Science Translational Medicine.

[4]  P. Filippakopoulos,et al.  Functions of bromodomain-containing proteins and their roles in homeostasis and cancer , 2017, Nature Reviews Molecular Cell Biology.

[5]  John W. Cassidy,et al.  A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds , 2016, Cell.

[6]  Henning Hermjakob,et al.  The Reactome pathway Knowledgebase , 2015, Nucleic acids research.

[7]  James E. Bradner,et al.  Response and resistance to BET bromodomain inhibitors in triple negative breast cancer , 2015, Nature.

[8]  D. Ayer,et al.  Interactions between Myc and MondoA transcription factors in metabolism and tumourigenesis , 2015, British Journal of Cancer.

[9]  Adam L Cohen,et al.  Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP , 2015, Proceedings of the National Academy of Sciences.

[10]  Ruili Huang,et al.  Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells , 2014, Breast Cancer Research.

[11]  A. Tan,et al.  Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer , 2014, Molecular Cancer.

[12]  D. Ayer,et al.  Coordination of nutrient availability and utilization by MAX- and MLX-centered transcription networks. , 2013, Cold Spring Harbor perspectives in medicine.

[13]  P. Marcom,et al.  Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort , 2013, Annals of Surgical Oncology.

[14]  S. Inoue,et al.  BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival , 2013, The Journal of experimental medicine.

[15]  D. Lobo,et al.  Thioredoxin interacting protein and its association with clinical outcome in gastro-oesophageal adenocarcinoma , 2013, Redox biology.

[16]  Reid C Thompson,et al.  Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma , 2013, Clinical Cancer Research.

[17]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[18]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[19]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[20]  David R. Kelley,et al.  Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.

[21]  S. Powell,et al.  BRCA1 and BRCA2: different roles in a common pathway of genome protection , 2011, Nature Reviews Cancer.

[22]  H. Nishiyama,et al.  Thioredoxin-interacting protein suppresses bladder carcinogenesis. , 2011, Carcinogenesis.

[23]  P. Sandy,et al.  Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.

[24]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[25]  T. Choe,et al.  TXNIP potentiates Redd1-induced mTOR suppression through stabilization of Redd1 , 2011, Oncogene.

[26]  C. Backendorf,et al.  ROS quenching potential of the epidermal cornified cell envelope. , 2011, The Journal of investigative dermatology.

[27]  S. Werner,et al.  The cornified envelope: a first line of defense against reactive oxygen species. , 2011, The Journal of investigative dermatology.

[28]  K. Nose,et al.  Importance of mitochondrial dysfunction in oxidative stress response: A comparative study of gene expression profiles , 2011, Free radical research.

[29]  K. Ickstadt,et al.  Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer , 2010, Breast Cancer Research.

[30]  S. J. Flint,et al.  The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription. , 2008, Molecular cell.

[31]  P. Mullan,et al.  The role of BRCA1 in transcriptional regulation and cell cycle control , 2006, Oncogene.

[32]  Richard T. Lee,et al.  The Interaction of Thioredoxin with Txnip , 2006, Journal of Biological Chemistry.

[33]  C. Deng,et al.  BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution , 2006, Nucleic acids research.

[34]  Robin A Roberts,et al.  A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis. , 2005, Blood.

[35]  Chae Young Hwang,et al.  Tumor suppressor VDUP1 increases p27(kip1) stability by inhibiting JAB1. , 2005, Cancer research.

[36]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[37]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[38]  E. Rosen,et al.  BRCA1 Induces Antioxidant Gene Expression and Resistance to Oxidative Stress , 2004, Cancer Research.

[39]  R. Tjian,et al.  Bromodomains mediate an acetyl-histone encoded antisilencing function at heterochromatin boundaries. , 2003, Molecular cell.

[40]  P. Steinert,et al.  Assembly of the epidermal cornified cell envelope. , 2001, Journal of cell science.

[41]  Curtis C. Harris,et al.  Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis , 2001, Nature Genetics.

[42]  C. Deng,et al.  Roles of BRCA1 and its interacting proteins , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[43]  Alexander Kinev,et al.  BRCA1 Is Associated with a Human SWI/SNF-Related Complex Linking Chromatin Remodeling to Breast Cancer , 2000, Cell.

[44]  H. Um,et al.  Vitamin D3 Up-Regulated Protein 1 Mediates Oxidative Stress Via Suppressing the Thioredoxin Function1 , 2000, The Journal of Immunology.

[45]  M. Matsui,et al.  Identification of Thioredoxin-binding Protein-2/Vitamin D3 Up-regulated Protein 1 as a Negative Regulator of Thioredoxin Function and Expression* , 1999, The Journal of Biological Chemistry.

[46]  M. Erdos,et al.  BRCA1 inhibition of estrogen receptor signaling in transfected cells. , 1999, Science.

[47]  R. Yarden,et al.  BRCA1 interacts with components of the histone deacetylase complex. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[48]  J. Minna,et al.  Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. , 1998, Cancer research.

[49]  R. Young,et al.  BRCA1 is a component of the RNA polymerase II holoenzyme. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[51]  H. DeLuca,et al.  Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3. , 1994, Biochimica et biophysica acta.

[52]  G. Di Trapani,et al.  Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. , 2009, Molecular nutrition & food research.

[53]  J. Haveman,et al.  Clonogenic assay of cells in vitro , 2006, Nature Protocols.

[54]  P. Olive,et al.  The comet assay: a method to measure DNA damage in individual cells , 2006, Nature Protocols.